240 related articles for article (PubMed ID: 36405648)
1. Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
Zhao D; Long X; Wang J
Drug Des Devel Ther; 2022; 16():3947-3955. PubMed ID: 36405648
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
Zeng Y; Arisa O; Peer CJ; Fojo A; Figg WD
Semin Oncol; 2024; 51(1-2):19-24. PubMed ID: 37880048
[TBL] [Abstract][Full Text] [Related]
3. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
[TBL] [Abstract][Full Text] [Related]
5. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
7. Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review).
Zhao D; Long X; Wang J
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34812476
[TBL] [Abstract][Full Text] [Related]
8. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
10. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Sulai NH; Tan AR
Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
12. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
13. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
17. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibition in Cancer: An Update on Clinical Development.
Sachdev E; Tabatabai R; Roy V; Rimel BJ; Mita MM
Target Oncol; 2019 Dec; 14(6):657-679. PubMed ID: 31625002
[TBL] [Abstract][Full Text] [Related]
19. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
20. Transporter‑mediated drug‑drug interactions involving poly (ADP‑ribose) polymerase inhibitors (Review).
Zhao D; Long X; Wang J
Oncol Lett; 2023 Apr; 25(4):161. PubMed ID: 36936025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]